RB1 and neoplasm: To determine whether the findings above are clinically relevant, the expression of DILA1 and Cyclin D1, p-D1(Thr286), p-Rb(Ser780), and Ki67 protein was evaluated in the primary tumor samples from 190 ER-positive breast cancer patients who received adjuvant tamoxifen treatment.